US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?
Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.
You may also be interested in...
Jatenzo clears US FDA 15 months after second negative advisory committee review.
US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.
Two oral testosterone therapies solicited similar concerns, but sometimes different votes from advisory committee members on recommending approval.